- Protocol No.
- Prinicipal Investigator
- Ma, Patrick
- Phase III
- Age Group
- Secondary Protocol No.
- DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R)
- The general aim of the trial is to determine the effectiveness of adding durvalumab to standard first line chemotherapy with cisplatin and pemetrexed in advanced malignant pleural mesothelioma.
The specific objectives (endpoints) of this trial are to determine:
1. Overall survival
2.PFS (by mRECIST 1.1 for MPM and iRECIST)
3.Objective tumour response [(OTR) by mRECIST 1.1 for MPM and iRECIST]
4.Adverse events (CTCAE v5.0)
5.Health-related quality of life (HRQL, EORTC QLQ-C30, QLQ LC-29, EQ-5D-5L)
6.Healthcare resource use relative to outcomes (incremental cost-effectiveness)
- Applicable Disease Sites
- Participating Institutions
- Hershey Medical Center